VNRX VolitionRx Limited Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
14:17
Jan 20
Jan 20
VNRX vet test 50-state and Asia expansion
The author argues VolitionRx is shifting from science to commercial product as Nu.Q Vet Cancer Test expands via Midwest Veterinary Laboratory across all 50 U.S. states starting February 2026 and via Bioguard in Taiwan/China. Management-cited TAM rises from about $100M for the U.S./Europe/Japan to nearly $150M with China, while annual checkups and senior wellness exams could turn the test into recurring revenue. Recent feline lymphoma data and $2.0M funding provide support, but the author flags micro-cap risks and execution risk on the rollouts.
HIGH
About VNRX Investor Commentary
Across the available history and selected sources, Buzzberg tracks VNRX (VolitionRx Limited) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Impossible-Hair1343.